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ABSTRACT 
 
     Postmenopausal osteoporosis is caused by a sharp decrease in estrogen levels leading to an increased rate 
of bone remodeling. Dietary supplements are preferred as alternative therapeutic options for many women 
instead of estrogen therapy. These alternative therapies include the use of natural substances such as soy 
isoflavones due to their weak estrogenic activity and affinity for estrogen receptors. 
Present study was carried out as a "before and after clinical trial" on 25 postmenopausal women aged 45-64 
years. Soy protein at 35g level containing 98.3mg isoflavones (containing 47.2 genistein and 37.8 daidzein) 
were given to subjects daily for 12 weeks. Blood and urine samplings were done in 3 stages, in the beginning 
and at the end of 6th and 12th week. Repeated measurement analysis was employed to analyze any possible 
changes in food intake and biochemical variables in 3 stages. The level of significance was set at below 5 
percent (P<0.05). Mean body mass index and physical activity level had no change and mean daily intake of 
macronutrients and important micronutrients were not different at 6 and 12 weeks compared to the start of the 
study The results showed a total serum alkaline phosphatase (TALP) significant increase while the other bone 
formation indicators namely osteocalcin and insulin growth factor binding protein (IGFBP3) did not change 
significantly. These data suggest that soy protein or its isoflavones may increase bone formation by 
supplementation. 
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INTRODUCTION 
     Postmenopausal osteoporosis is caused by a 
sharp decrease in estrogen levels that leads to an 
increased rate of bone remodeling [1]. Currently 
estrogen therapy, especially bisphosphonates, 
calcitonine and raloxifene is used to treat 
postmenopausal osteoporosis [2]. Although 
hormone replacement therapy is effective in 
reducing postmenopausal bone loss [3, 4], it is 
associated with a higher risk for breast, 
endometrial, and ovarian cancer; cardiovascular 
disease; venous thromboembolism and stroke [4, 
5]. Dietary supplements are preferred as 
alternative therapeutic options for many women 
[6]. These alternative therapies include the use of 
natural or plant-based substances such as soy 
isoflavones [7-10]. Phytoestrogens, including 
isoflavones, are being used as an alternative 
therapeutic agent to ERT because of their weak 
estrogenic activity and affinity for estrogen 
receptors, specifically estrogen receptor-α (ER-α) 
and estrogen receptor-β (ER-β), which are present 
in bone, brain, bladder, and vascular epithelia [11, 
12]. Isoflavones stimulate osteogenesis at low 
concentrations and inhibit osteogenesis at high 
concentrations in osteoblasts and osteoprogenitor 
cells [13, 14]. Isoflavones also influence the 
production of cytokines derived from osteoblasts 
and osteoprogenitor cells in a similar biphasic 
manner [15]. By contrast, bone resorption data 
show that, instead of having biphasic effects, 
isoflavones only inhibit osteoclast formation and 
activity [16]. Phytoestrogens can act by binding or 
phosphorylation, resulting in the commitment of 
osteoprogenitor cells to differentiate into either 
osteoblasts or adipocytes [13]. Evidence from 
epidemiological studies of elderly women in 
Asian nations suggests that high consumption of 
isoflavones from soy products may be protective 
against fractures in comparison with Western 
 




populations [17]. Because of the differences in 
experimental design, results from human studies 
are variable and conflicting. It seems finding the 
critical doses of phytoestrogens that exert 
beneficial effects on bone is very important to 
preventive interventions. Thus, the aim of this 
study was to evaluate the formative effects of 
isoflavone supplementation on postmenopausal 
females' bone in I.R. of Iran.  
 
MATERIALS AND METHODS 
Participants  
     This study recruited 25 postmenopausal 
women aged 45-64 years, who had experienced at 
least 1–10 years of menopause according to their 
own statements. They were recruited between 
January 2004 and March 2004 from osteoporosis 
clinic of Endocrine Research Centre at Tehran 
Medical University (Shariati Hospital) for bone 
density measurement. 
Study design 
Present study was carried out as a "before and 
after type of clinical trial" to examine how bone 
formation markers were affected by soy 
isoflavone supplementation for 12 weeks. 
Baseline assessment and sample collection 
 Information on weight, height, body mass index, 
two 24-hr food consumption recall and physical 
activity were collected at the start, 6 and 12 weeks 
of the study. Blood and urine samplings were 
done in 3 stages, in the beginning and at the end of 
the 6th and 12th week. Blood and urine samples 
were kept frozen until the end of the twelfth week 
at -80℃. Serum biochemical indicators were 
measured on the same day for all samples. 
Intervention 
Soy protein at 35g level containing 98.3mg 
isoflavones were given to subjects daily. 
Isoflavones profiles of utilized soy protein are 
shown in table 1. Subjects were provided with a 
special cup for measuring soy and cooking 
instructions were also given to the subjects. A few 
reductions were done in some groups' serving of 
food like meat and bread to avoid exceeded intake 
of protein. They were emphasized to not change 
their food habits and physical activity level.  
Markers of bone formation 
 Total alkaline phosphatase was assayed 
calorimetrically with Hitachi 902 autoanalyzer, 
osteocalcin by IRMA method using Biosource kit 
and Wizard gamacounter, IGFBP3 by ELISA using 
Biosources diagnostics. Urinary creatinine was 
determined by calorimetric method [18]. 
Table 1 – Isoflavones profile of the consumed soy protein. 
Isoflavones profile Milligram per gram 









 We used Food Processor software and SPSS 
program for food consumption survey and 
statistical analysis of the data, respectively. All 
values are presented as the mean ± S.D. 
Quantitative variables were then examined by 
Kolmogrof-Smirnof (KS) to ensure normality of 
distribution. Repeated measurement analysis was 
employed to analyze any possible changes in food 
intake, intervening and biochemical variables in 3 
stages. The purpose of this analysis was to ensure 
lack of significant changes of the variables. The 




   From among 25 participants, 10 subjects were 
excluded for reasons such as irregular soy intake, 
gastrointestinal disorders, traveling, stroke and 
HRT. 15 women, therefore, remained in this 
intervention till the end of study. Table 2 shows the 
characteristics of subjects who participated in our 
assessment. Mean body mass index and physical 
activity level had no change and mean daily intake 
of macronutrients as well as important 
micronutrients did not differ at 6 and 12 weeks 
compared to the start of the study (Table 3).To 
analyze changes in 3 stages repeated measurement 
analysis was utilized. Three months soy protein 
supplementation resulted in a significant increase 
for total serum alkaline phosphatase (TALP) while 
the other bone formation indicators namely 
osteocalcin and insulin growth factor binding 
protein (IGFBP3) remained unchange. 
 
 Table 2. Subjects' characteristic data at the beginning of 
the study (n=15). 
Characteristic data Mean ± SD (n = 15) 
Age (year) 52.9 ± 4.3 
Duration of Menopause 5.47 ± 3.4 
Weight (kg) 68 ± 7.5
 
Height (m) 157.2 ± 7.2 
BMI (kg/m
2
) 27.4 ± 3
 
 





Table 3. Subjects mean food intake in 3 stages of the study (n=15). 
Macro/Micronutrients 
intakes 
at the start 6 weeks 12 weeks P value
 ٭٭
Energy (kcal) 1933.4 ± 302.5
 
2033.2 ± 420.3 1902.8 ± 308.6 NS
 
Protein (g) 74.6 ± 12.3 71.9 ± 17.4 74.8 ± 10.2 NS 
Fat (g) 62 ± 13.5 65.45 ± 17.25 63.68 ± 13.08 NS 
Carbohydrate (g) 269.14 ± 53.31 282.62 ± 66.5 257.48 ± 59.65 NS 
Calcium (mg) 999.3 ± 460.2 966.8 ± 443.7 1014 ± 436 NS 
Phosphorus(mg) 873.2 ± 228.9 853.1 ± 273.9 866.4 ± 200.6 NS 
Fiber (g) 14.72
 
± 2.79 13.91 ± 2.91 14.4 ± 2.69 NS 
 Mean ± SD ٭
 .(significant level was set at below 5 percent (P<0.05 ٭٭
 
Table 4. Change of bone formation markers in three stage of study. 
Bone metabolism 
biomarkers٭ 
Stage of study Mean ± SD (n = 15) P value
†
 
TALP At the start 237.5 ± 85.4 <0.05 
6 weeks 300.4 ± 294.1 
12 weeks   281.3 ± 80.5 
OC At the start 11.4 ± 4.8 NS
 
6 weeks 12.7 ± 5.7 
12 weeks   11.5 ± 4.8 
IGFBP3 At the start 3304.6 ± 728.6 NS 
6 weeks 3221.6 ± 534.4 
12 weeks   3103.9 ± 639.8 
 TALP: Total alkaline phosphatase (gr/dl); OC: Osteocalcin (ng/ml); IGFBP3: Insulin like growth factor binding protein 3 ٭
(ng/ml) 
† significant level was set at below 5 percent (P<0.05). 
 
DISCUSSION  
   In the present study, the daily consumption of 
35 g soy protein containing 47.2 genistein and 
37.8 daidzein for three months resulted in 
significant increase in TALP in menopausal 
women with osteopenia, while other parameters 
were not significantly difference. In Arjmandi et 
al studies on rats a slight insignificant increase 
in TALP was seen [19-21] and their study on 
postmenopausal women showed, biomarkers of 
bone formation, i.e. osteocalcein, IGF-I and 
BSAP were all significantly elevated [22]. 
Totally, comprehensive human studies on the 
effect of soy on biomarkers of bone formation 
have been reported to either increase [23, 24] or 
no change [25,26] as a result of soy 
supplementation. In monkeys soy protein 
consumption induced a significant fall in TALP 
after 12 weeks [27].  In animal models such as 
monkey only 30 to 50% of daidzein was 
converted to equol and it has been shown that 
equol possesses more estrogen-like properties 
than daidzein. This is why isoflavone efficacy 
has been less pronounced in monkeys and the 
results have been reported as reduced TALP 
levels [28, 29].  
Albertazzi observed genistein as a component 
of soy isoflavone reduced osteocalcin, a marker 
of bone formation, by 3.6% compared to 
baseline and 0.31% compared to placebo (30). 
In another study, at 24 months, genistein 
significantly increased the levels of bone-
specific alkaline phosphatase and insulin-like 
growth factor I [31]. 
Vitolins et al. reported that daily consumption 
of 25 g soy protein with 5, 42 or 58 mg 
isoflavones had no bone preserving effects in 
peri- and post-menopausal women in a two-year 
study [32]. Findings from two studies have 
shown similar effects of soy protein and its 
isoflavones on bone [33, 34]. In contrast, other 
studies have suggested that isoflavone-rich soy 
milk containing 80 to 90 mg isoflavones [35] or 
soy products with 40 to 60 mg isoflavones on a 
daily basis [36] can exert bone protective 
effects. 
Atkinson et al showed that loss of lumbar spine 
bone mineral content and bone mineral density 
was significantly lower in the women taking the 
 




isoflavone supplement than in those taking the 
placebo. There were no effects on markers of 
bone resorption, but bone formation markers 
like bone-specific alkaline phosphatase were 
significantly increased (P=0.04) in the 
intervention group compared with placebo in 
postmenopausal women [37].  
Isoflavone intervention stimulated bone 
formation and significantly increased serum 
BAP. These effects occur even with 
<90 mg/day of isoflavones consumption for less 
than 12 weeks [38]. Based on Devareddy et al 
study results, soy protein and its isoflavones 
have a modest eneficial effect in established 
osteoporosis as was evident by improvements in 
certain structural parameters and higher doses 
of isoflavones may be required to reverse the 
loss of tibial microstructural properties [39]. 
Additionally, the other study indicate that soy 
protein isoflavones increase mRNA levels of 
bone-specific alkaline phosphatase, an indicator 
of osteoblastic activity, and several of bone 
matrix proteins including type I collagen and 
osteocalcin in ovariectomized rats [40] which 
can explain the alkaline phosphatase increases 
observed in our study. 
 
CONCLUSION 
   According to several studies, soy isoflavones 
induce bone formation based on at least three 
mechanisms: stimulation of activity, 
proliferation, and differentiation of osteoblasts; 
protection of osteoblasts from apoptosis and 
enhancement of bone formation rate as assessed 
by bone histomorphometry [41-44]. Based on 
these data it can be concluded that soy protein 
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